Corey S. Cutler, MD, MPH, FRCPC

Articles

Steroid-Refractory Chronic GVHD: Selecting and Sequencing Therapy

August 15th 2022

Following their review of available treatment for steroid refractory chronic GVHD, experts consider how they would optimally select and sequence therapy.

Treatment Armamentarium for Steroid-Refractory Chronic GVHD

August 15th 2022

Comprehensive discussion on each of the 3 standard-of-care treatment options for patients with steroid refractory chronic GVHD.

Frontline Treatment Strategies for Chronic GVHD

August 8th 2022

An overview of the frontline treatment armamentarium for patients diagnosed with chronic graft versus host disease.

Improving the Early Identification of Chronic Graft Versus Host Disease

August 8th 2022

Shifting their focus to chronic graft versus host disease, panelists emphasize the importance of early identification and diagnosis.

Identifying the Role of the Microbiome in HSCT and GVHD

August 1st 2022

Expert panelists review the role of the microbiome in the context of hematopoietic stem cell transplantation and steroid-refractory acute GVHD.

Steroid-Refractory GVHD: Enrolling Patients on Clinical Trials

August 1st 2022

Key opinion leaders highlight the value of clinical trials and share their perspective on enrolling patients in the setting of acute GVHD.

Overview of Therapy for Steroid-Refractory Acute Graft Versus Host Disease

July 25th 2022

Comprehensive discussion on the treatment options available for patients diagnosed with steroid-refractory acute GVHD.

What is the Role of Biomarker Testing in GVHD?

July 25th 2022

A brief review of the evolving utilization of biomarker testing in acute graft versus host disease, particularly for prognostic evaluation.

Challenges in Making a Diagnosis of Acute GVHD

July 18th 2022

Focusing on acute graft versus host disease, panelists consider tools and methods that help to overcome challenges in making a differential diagnosis.

Educating Patients and Caregivers on the Impact of Graft Versus Host Disease

July 18th 2022

Expert perspectives on how best to educate patients and caregivers on graft versus host disease symptoms and quality of life.

Graft Versus Host Disease: Optimizing Prophylaxis Techniques

July 11th 2022

Shared insight on standard-of-care prophylactic methods employed in the management of patients with graft versus host disease.

Understanding Pathophysiology and Risk of Graft Versus Host Disease

July 11th 2022

Expert panelists spearhead a discussion on the pathophysiology driving both acute and chronic graft versus host disease.

HSCT Approaches to Retain GVL While Preventing GVHD

May 6th 2022

Expert perspectives on novel transplantation strategies to prevent or improve outcomes in graft-versus-host disease.

Novel Targeted Agents in GVHD: The FLIGHT and AGAVE-201 Trials

May 6th 2022

Brief insight on the FLIGHT and AGAVE-201 trials in chronic GVHD, which analyzed itacitinib, a JAK inhibitor, and axatilimab, a CSF1R inhibitor, respectively.

Chronic GVHD: Novel Treatment Approaches With Approved Agents

April 29th 2022

Considerations for novel treatment approaches with approved agents in combination or the frontline setting of chronic graft-vs-host disease.

Selecting Second-Line Therapy for Chronic GVHD

April 29th 2022

Shared insight on how best to select ibrutinib, belumosudil, or ruxolitinib for patients with steroid-refractory chronic graft-vs-host disease.

Chronic GVHD: Real-World Use of Ruxolitinib

April 22nd 2022

Closing out his summation of ruxolitinib in chronic GVHD, Yi-Bin Chen, MD, considers how real-world use compares with the REACH3 trial results.

REACH3 Trial: Approval of Ruxolitinib in Chronic GVHD

April 22nd 2022

Comprehensive insight on the design and results of REACH3, which analyzed ruxolitinib as second-line therapy for chronic graft-vs-host disease.

Mechanism of Action of Ruxolitinib

April 15th 2022

In the context of chronic graft-vs-host disease, expert Yi-Bin Chen, MD, provides an overview of ruxolitinib’s mechanism of action.

Belumosudil’s Approval and Use in Chronic Graft-Vs-Host Disease

April 15th 2022

Haris Ali, MD, shares insight on belumosudil, a ROCK2 inhibitor approved in the management of chronic graft-vs-host disease.